Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age.

Abstract	Since 1987 Haemophilus influenzae b (Hib) conjugate vaccines have been licensed for use in children ages 18 months and older. Before licensure there were no clinical trials of a single dose of any conjugate vaccine in children ages 18 months or older. To fulfill this need we performed an age- and residence-matched case-control study of the efficacy of Hib vaccines. In our study population the protective efficacy (PE) of Hib-diphtheria toxoid conjugate vaccine was 88% (95% confidence interval, 45 to 98%). No vaccine failures were observed with Hib oligosaccharide CRM197 diphtheria protein conjugate vaccine, but usage was not sufficient to establish efficacy: PE = 100% (95% confidence interval, -37 to 100%). The protective efficacy of Hib capsular polysaccharide vaccine was 18% (95% confidence interval -487 to 89%). We conclude that for children ages 18 to 60 months a single dose of the Hib conjugate vaccine, PRP-D, is protective against invasive Hib infections. Consistent with most studies Hib polysaccharide vaccine provided suboptimal protection.
Authors	A M Loughlin, C D Marchant, S Lett, E D Shapiro
Journal	The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 11 Issue 5 Pg. 374-9 (May 1992) ISSN: 0891-3668 [Print] United States
PMID	1630857 (Publication Type: Journal Article)
Chemical References	Bacterial Proteins Bacterial Vaccines Diphtheria Toxoid Haemophilus Vaccines Haemophilus influenzae type b polysaccharide vaccine Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate Polysaccharides, Bacterial HibTITER protein, Haemophilus influenzae
Topics	Bacterial Capsules Bacterial Proteins Bacterial Vaccines Case-Control Studies Child, Preschool Diphtheria Toxoid Female Haemophilus Infections (epidemiology, prevention & control) Haemophilus Vaccines Haemophilus influenzae Humans Infant Male Massachusetts (epidemiology) Polysaccharides, Bacterial Statistics as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!